NCT04207489

Brief Summary

Prospective registry study of endoscopic submucosal injection of indocyanine green before laparoscopic radical resection for colorectal cancer

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 17, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 23, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

April 15, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 25, 2020

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 28, 2021

Completed
Last Updated

August 24, 2020

Status Verified

August 1, 2020

Enrollment Period

8 months

First QC Date

December 17, 2019

Last Update Submit

August 20, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • The imaging effect of indocyanine green

    The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.

    During the operation

Study Arms (1)

endoscopic submucosal injection of indocyanine green

Procedure: endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer

Interventions

Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.

endoscopic submucosal injection of indocyanine green

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who were to undergo indocyanine green fluorescence imaging for laparoscopicradical operation of colorectal cancer.

You may qualify if:

  • Patients who were to undergo indocyanine green fluorescence imaging for laparoscopic radical operation of colorectal cancer.

You may not qualify if:

  • have simultaneously other cancer
  • have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases
  • have gastrointestinal surgery
  • Indocyanine green or iodine allergy
  • the period is too late or the tumor is too large to carry on a laparoscopic surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

the First Hospital of Jilin University

Changchun, Jilin, 130021, China

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Dong Yang, Master

    The First Hospital of Jilin University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hong Xu, Professor

CONTACT

Dong Yang, Master

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Month
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisted Investigator

Study Record Dates

First Submitted

December 17, 2019

First Posted

December 23, 2019

Study Start

April 15, 2020

Primary Completion

December 25, 2020

Study Completion

April 28, 2021

Last Updated

August 24, 2020

Record last verified: 2020-08

Data Sharing

IPD Sharing
Will not share

Locations